362 completed, 79 unknown, 50 terminated, 18 active not recruiting. 150 Phase 4, 132 Phase 2, 110 Phase 3, 75 Phase 1, 58 Not applicable.
Follow Tenofovir: new trials by email Literature Review of Tenofovir trials Research Report on Tenofovir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV Switch from an ART regimen containing lamivudine (3TC) or emtricitabine (FTC) + tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) to DOR/ISL, Switch from an nucleoside reverse transcriptase inhibitor (NRTI)-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL, Continue SoC ART - Epigenetic Aging | Phase 2 | Not yet recruiting | The University of Texas Health Science Center, Houston | 60 | 2026-10-30 | 2026-10-13 |
| Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIV Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Doravirine 100mg, Tenofovir disoproxil fumarate 300mg / Lamivudine 300mg / Dolutegravir 50mg - HIV (Human Immunodeficiency Virus), Sleep | Phase 4 | Not yet recruiting | University of Witwatersrand, South Africa | 40 | 2026-10-05 | 2026-10-06 |
| Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study Dolutegravir (DTG) AND Tenofovir alafenamide (TAF), Tenofovir Disoproxil Fumarate, Dolutegravir - Healthy Volunteer, Weight Gain | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 120 | 2026-09-24 | 2026-09-29 |
| Efficacy and Safety of Doravirine in the Rapid Initiation Doravirine / lamivudine/ Tenofovir Disoproxil Oral Tablet - HIV-1-infection | Phase 4 | Recruiting | Fundación Huésped | 100 | 2026-09-16 | 2026-09-23 |
| Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response TQA3605 tablets Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis B | Phase 3 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 930 | 2026-09-01 | 2026-10-02 |
| Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir Regimens Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, Tenofovir, Lamivudine and Efavirenz Disoproxil Fumarate Tablets - HIV, Art Therapy | Phase 4 | Not yet recruiting | Shanghai Public Health Clinical Center | 60 | 2026-06-01 | 2026-06-08 |
| Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection Combination of Dolutegravir + Tenofovir DF for treatment of HTLV-1 infection, Dolutegravir (DTG) - HTLV-1 Infection, HTLV I Associated Myelopathies | Phase 2 | Recruiting | Carlos Brites | 146 | 2026-05-07 | 2026-06-02 |
| Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF) - HIV Infections | Recruiting | Gilead Sciences | 3000 | 2026-03-17 | 2026-10-21 | |
| Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome Tenofovir (TDF) and Emtricitabine (FTC), Placebo - Aicardi Goutières Syndrome | Phase 1 / Phase 2 | Withdrawn | Children's Hospital of Philadelphia | 2025-12-01 | 2025-05-01 | |
| A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) MK-8527, Emtricitabine/tenofovir disoproxil (FTC/TDF), Placebo matched to MK-8527 - Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 4580 | 2025-11-10 | 2026-10-20 |
| Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment Dolutegravir 50mg Tab, Dolutegravir/Lamivudine 50 MG-300mg Oral Tablet [DOVATO], Dolutegravir plus Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC) - Tuberculosis, HIV | Phase 3 | Recruiting | Johns Hopkins University | 150 | 2025-09-18 | 2026-09-11 |
| Improving Access to PrEP (HIV Prevention Medication) for People in Underserved Areas of Rio de Janeiro Oral Pre-Exposure Prophylaxis (PrEP) (Tenofovir Disoproxil Fumarate/Emtricitabine), Community-Based PrEP Delivery Model, Telehealth and mHealth Support - HIV Infections | Not applicable | Recruiting | Oswaldo Cruz Foundation | 400 | 2025-09-01 | 2026-05-13 |
| Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases. PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases. - Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Hospital of Xuzhou Medical University | 30 | 2025-09-01 | 2025-08-21 |
| Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders. PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoproliferative Disorders. - EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor | Phase 1 / Phase 2 | Not yet recruiting | The Affiliated Hospital of Xuzhou Medical University | 50 | 2025-09-01 | 2025-08-21 |
| Research on the Psychological Status of Patients With HIV-1 Infection All kinds of INSTI medications, All kinds of conventional medications - HIV-1-infection, Anxiety Depression | Not yet recruiting | Shanxi Bethune Hospital | 500 | 2025-08-01 | 2025-07-23 | |
| Effect of Long-Term Use of Tenofovir (TDF) on Bone Density in Patients With Chronic Hepatitis B TDF (Tenofovir) - Tenofovir Disoproxil Fumarate, Bone Density | Not yet recruiting | Assiut University | 172 | 2025-05-22 | 2025-05-25 | |
| Effect of Tenofovir (TDF) on Renal Function in Patients With Chronic Hepatitis B Tenofovir Disoproxil Fumarate (TDF) - Tenofovir Disoproxil Fumarate, Renal Function Disorder | Not yet recruiting | Assiut University | 172 | 2025-04-10 | 2025-04-04 | |
| TAF in Early/Middle Pregnancy With CHB TAF, TDF - Hepatitis B Infection, Pregnant Women | Phase 4 | Enrolling by invitation | The Third Affiliated Hospital of Guangzhou Medical University | 816 | 2025-03-31 | 2026-06-25 |
| DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection Doravirine + tenofovir DF + lamivudine, Dolutegravir + tenofovir DF + lamivudine or emtricitabine - HIV-1-infection | Phase 3 | Recruiting | ANRS, Emerging Infectious Diseases | 610 | 2025-01-27 | 2026-07-27 |
| Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV Gammora® - HIV Seropositivity | Phase 2 | Active not recruiting | Federal University of São Paulo | 40 | 2025-01-01 | 2026-06-01 |
Showing 20 of 558. Sign in to see all of them.
HIV Infections (169) · Hepatitis B, Chronic (109) · Hepatitis B (80) · Acquired Immunodeficiency Syndrome (56) · Hepatitis (12) · Infections (10) · Carcinoma, Hepatocellular (8) · Hepatitis C (8) · Liver Cirrhosis (8) · Hepatitis D (6) · Acute-On-Chronic Liver Failure (5) · HIV Seropositivity (5) · Tuberculosis (5) · Virus Diseases (5) · Fibrosis (4)
Gilead Sciences (47) · National Institute of Allergy and Infectious Diseases (NIAID) (36) · ANRS, Emerging Infectious Diseases (14) · CONRAD (13) · University of North Carolina, Chapel Hill (13) · Third Affiliated Hospital, Sun Yat-Sen University (12) · Bristol-Myers Squibb (11) · Janssen Research & Development, LLC (9) · ViiV Healthcare (9) · French National Agency for Research on AIDS and Viral Hepatitis (8) · Kirby Institute (8) · Merck Sharp & Dohme LLC (8) · Centers for Disease Control and Prevention (7) · GlaxoSmithKline (7) · University of California, San Diego (7)
United States (201) · China (57) · France (51) · Spain (50) · Canada (46) · United Kingdom (46) · South Africa (45) · South Korea (42) · Germany (36) · Italy (35) · Taiwan (35) · Thailand (32) · Australia (31) · New Zealand (24) · Poland (24)
Liang Peng, Doctor (7) · Sybil Hosek, PhD (5) · Lynda Stranix-Chibanda, MBChB, MMED (4) · Calvin Q Pan, MD (3) · Craig Hendrix, MD (3) · John Flaherty, PharmD (3) · Albert Liu, MD, MPH (2)
PMID 37771546, PMID 19052126, PMID 25987775, PMID 27572401, PMID 20955704, PMID 22972843, PMID 23234725, PMID 23364953, PMID 23939953, PMID 25179493, PMID 25277773, PMID 25532501, PMID 25596179, PMID 25788199, PMID 25800784, PMID 26453773, PMID 27658343, PMID 28215615, PMID 28404091, PMID 28404092, PMID 29756595, PMID 29933096, PMID 30038044, PMID 30795958, PMID 30833068, PMID 30876946, PMID 31136052, PMID 31179503, PMID 32766890, PMID 34878438, PMID 34913844, PMID 37561058, PMID 38340811, PMID 39327857, PMID 40354181, PMID 40672760, PMID 41280318, PMID 41869811, PMID 12472227, PMID 15155205, PMID 15199325, PMID 15470215, PMID 15668539, PMID 16391218, PMID 16421366, PMID 16470118, PMID 16470119, PMID 16530509, PMID 16673294, PMID 16871563
2014 (9), 2009 (7), 2015 (6), U01AI068633 (5), 2008 (3), 2019 (3), U01AI068636 (3), 2004 (2), 2005 (2), 2016 (2), 2023 (2), K23AI074390 (2), R01MH110051 (2), U19AI082637 (2), 2017 (1)